media – Page 172 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Pharmaceutical companies connect with DeepSeek to reduce costs, and the cost of accurate error correction of general models is high

DeepSeek is penetrating into various industries. In February 2025, the domestic large model DeepSeek-R1 was fully open source and adapted to multiple fields, and AI medical care also entered a new stage of technology integration and industry reconstruction. Many companies including Aimi Vaccine, Hengrui Medicine, and Zhiyun Health announced that they are combining with AI large models such as DeepSeek. Take the recent announcement of Aimi Vaccine as an example. It stated that as a leading vaccine company in China, the group actively responded to the national “AI+” industrial development strategy and fully deployed access to the DeepSeek large model. However, the financial report of Aimi Vaccine shows that it has faced continuous losses in recent years. To what extent can DeepSeek reduce costs and increase efficiency? Many industry analysts consulted by Blue Whale Finance all said that overall, they are optimistic about the application of AI big models such ...
- Source: drugdu
- 445
- February 27, 2025
Authorized cooperation accelerates the pace of Chaoyong pharmaceutical companies going global

Recently, Shiyao Group announced that its subsidiary Shiyao Jushi has signed an exclusive authorization agreement with Radiance Biopharma for the antibody conjugate drug SYS6005. Since 2025, several pharmaceutical companies, including Xinda Biotechnology and Xiansheng Pharmaceutical, have signed large orders with potential amounts of up to 1 billion US dollars. Industry insiders believe that the overall progress of domestic new drug research and development is commendable, and Chinese pharmaceutical companies with strong research and development capabilities are expected to compete with foreign-funded enterprises in the global market. They are optimistic about the prospects of domestic new drug research and development and going global in 2025. Multiple products achieve overseas authorization According to the announcement from Shiyao Group, Shiyao Giant Stone has agreed to grant Radiance Biopharma exclusive authorization to develop and commercialize SYS6005 in the United States, European Union, United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, ...
- Source: drugdu
- 424
- February 26, 2025
11.4 billion, Boston Science has a big move

On February 21, 2025, Boston Scientific (NYSE: BSX) announced that its fully funded subsidiary, American Medical Systems Europe B.V. (“AMS Europe”), has priced a total of 1.5 billion euros (approximately RMB 11.377 billion) in notes (a type of bond issuance). The funds obtained from this issuance, along with the company’s cash on hand, will be used for debt repayment, working capital, and potential future acquisitions. As of February 21st, Boston Scientific’s latest stock price is $104.49 per share, with a total market value of $154 billion, reaching its highest point since going public. 01. Issuing bonds worth billions, PFA’s performance skyrocketed by 172% The notes issued this time consist of two transactions, one with a total principal of 850 million euros and an interest rate of 3.000%, due in 2031; The other principal amount is 650 million euros, with an interest rate of 3.250%, due in 2034. The bill will ...
- Source: drugdu
- 364
- February 26, 2025
9 Medical Devices Enter Innovation Channel

Recently, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 2 of 2025), intending to approve 9 medical devices to enter the innovation channel. 1. Peripheral arterial stent graft system: Jiangsu Pupeng Medical Technology Co., Ltd Pupeng Medical was established on December 16, 2019, and is a subsidiary of Jiangsu Zhenyi Medical Technology Co., Ltd. (hereinafter referred to as Zhenyi Medical). It is reported that Zhenyi Medical focuses on the cardiovascular disease field with extremely high mortality and disability rates, and the domestic market is still blank. Its business comprehensively covers multiple interventional treatment fields such as heart valves, peripheral and coronary arteries. It is the first platform enterprise to achieve one-stop innovative solutions for blood flow management on a global scale. In addition to the products that entered the innovation channel this time, Park Peng Medical also ...
- Source: drugdu
- 474
- February 26, 2025
【EXPERT Q&A】Is CE certification required for EU GPSR compliance? What are the conditions?

Drugdu.com expert’s response: The Relationship Between EU GPSR Compliance and CE Certification Mandatory Compliance with GPSR: GPSR (General Product Safety Regulation) is a regulation of the European Union aimed at ensuring that products sold on the market are safe and do not pose a harm to consumers. Compliance with GPSR regulations is mandatory for most products. Definition and Scope of CE Certification: CE certification is a product compliance mark indicating that a product meets the safety, health, and environmental protection requirements of the European Union. It primarily applies to certain specific categories of products, such as electronics and machinery. Relationship Between GPSR and CE Certification: GPSR compliance and CE certification are two different compliance systems, but they overlap in some aspects. The directives and standards upon which CE certification is based correspond to the safety requirements of GPSR, but their focuses and scopes of application differ. Not all products that need to ...
- Source: drugdu
- 466
- February 26, 2025
CMEF

Organiser：Reed Sinopharm Exhibitions Time：April 8th – 11th, 2025 Address：Shanghai National Convention and Exhibition Center Address: No. 333 Songze Avenue, Xujing Town, Qingpu District, Shanghai Exhibition hall：Shanghai National Convention and Exhibition Center Product range: Medical Imaging Area: Radiological products, ultrasound products, nuclear medicine products, molecular imaging, interventional products, etc. Operating Room Area: Hybrid operating rooms, integrated operating room solutions, surgical instruments, anesthesia machines, ventilators, monitors, operating room engineering, surgical lights, ceiling-mounted equipment booms, etc. In Vitro Diagnostics Area: Comprehensive laboratory solutions, clinical diagnostic equipment, diagnostic reagents, POCT (point-of-care testing), household diagnostic devices, etc. Rehabilitation and Physiotherapy Area: Rehabilitation equipment, assistive devices, traditional Chinese medicine treatments, physiotherapy equipment, medical high-frequency devices, etc. Orthopedics Zone: Orthopedic implants for joints, trauma, and spine; orthopedic surgical instruments and equipment; bone power tools, and other orthopedic-related products. Medical Informatization Area: System integrators, mobile healthcare, medical management, quality control, clinical hospital information management systems, IT equipment ...
- Source: drugdu
- 567
- February 25, 2025
HPV vaccine market is about to expand, and the Bio-Vaccine ETF (562860) rose 1.14% during the session

As of 10:13 on February 20, 2025, the CSI Vaccine and Biotechnology Index rose strongly by 1.13%, with constituent stocks Yifang Biotech rising by 7.45%, Dizhe Pharmaceuticals rising by 6.93%, Shuanglu Pharmaceuticals rising by 4.37%, and Wanze Shares, Dongbao Bio and other stocks following suit. Bio-Vaccine ETF (562860) rose by 1.14%, and the intraday turnover has reached 6.5605 million yuan. In terms of scale, the scale of Bio-Vaccine ETF has increased by 3.2427 million yuan in the past week, achieving significant growth. It is worth noting that the valuation of the CSI Vaccine and Biotechnology Index tracked by the fund is at a historical low, with the latest price-to-book ratio PB being 2.95 times, which is lower than the index’s 83.43% of the past five years, and the valuation cost-effectiveness is outstanding. Data shows that as of January 27, 2025, the top ten weighted stocks in the CSI Vaccine and ...
- Source: drugdu
- 379
- February 24, 2025
Over 1.2 billion US dollars! CSPC Pharmaceuticals ROR1 ADC reaches international licensing cooperation

On February 19, CSPC Pharmaceutical Group announced that its subsidiary CSPC Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”) has reached an important agreement with Radiance Biopharma. According to the agreement, Radiance Biopharma will obtain the exclusive development and commercialization rights of Jushi Bio’s independently developed SYS6005 project in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia and Canada. Jushi Bio will receive a down payment of US$15 million, a development and regulatory milestone amount of US$150 million, a sales milestone amount of US$1.075 billion, and a certain percentage of sales revenue. SYS6005: An innovative ADC drug SYS6005 is a monoclonal antibody-drug conjugate (ADC) independently developed by Jushi Bio. It can bind to specific receptors on the surface of tumors, enter cells through endocytosis and release toxins to kill tumor cells. SYS6005 uses Jushi Bio’s ...
- Source: drugdu
- 325
- February 24, 2025
Hengrui Medicine enters the children’s myopia track, this “myopia magic drug” is about to debut

Recently, Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, submitted a marketing authorization application for HR19034 Eye Drops (Atropine Sulfate Eye Drops) to the National Medical Products Administration, which has been accepted. This product is mainly used to prevent and control the progression of myopia in children and adolescents. According to the Yaozhi Data global drug analysis system, Hengrui Medicine’s HR19034 project started clinical trials in April 2021. After completing the Phase I trial, the company immediately started Phase II/Phase III research. According to Hengrui’s announcement, the project will complete a three-year clinical trial in August 2024. Research data showed that HR19034 was superior to the control group in terms of the primary endpoint and demonstrated good safety and tolerability in children with myopia. The most common application of atropine in ophthalmology is mydriasis. Atropine sulfate at a concentration of 1% is usually used for fundus examination and eye examination ...
- Source: drugdu
- 398
- February 24, 2025
Pfizer’s pan-KRAS inhibitor cancer drug approved for clinical trials

On February 17, the CDE official website announced that Pfizer’s Class 1 new drug “PF-07934040 Tablets” has obtained implicit approval for clinical trials and is intended to be developed to treat advanced solid tumors carrying KRAS mutations. PF-07934040 is a pan-KRAS inhibitor under development and is currently undergoing Phase 1 clinical trials internationally. According to Yaozhi data, this is the first time that the product has been approved for IND in China. According to Pfizer’s official website, PF-07934040 is a pan-KRAS “ON/OFF” inhibitor that has activity against wild-type (wt) KRAS and major mutant subtypes, and is inactive against NRAS or HRAS. PF-07934040 has been shown to bind to both the OFF (GDP-bound) and ON (GTP-loaded) states of KRAS wt, and has very low binding affinity to mutants, with a selectivity for binding to KRAS that is 5,000 times higher than HRAS/NRAS. https://news.yaozh.com/archive/45010.html
- Source: drugdu
- 519
- February 24, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.